Negative Association Between lncRNA *HOTTIP* rs3807598 C>G and Hirschsprung Disease

This article was published in the following Dove Press journal:
Pharmacogenomics and Personalized Medicine

Yi Zheng*
Zhenjian Zhuo*
Xiaoli Xie
Lifeng Lu
Qiuming He
Wei Zhong

Department of Pediatric Surgery,
Guangzhou Institute of Pediatrics,
Guangdong Provincial Key Laboratory of
Research in Structural Birth Defect
Disease, Guangzhou Women and
Children's Medical Center, Guangzhou
Medical University, Guangzhou 510623,
Guangdong, People's Republic of China

*These authors contributed equally to
this work

Background: Hirschsprung disease (HSCR) is a congenital disease that arises from defective intestinal neural system. lncRNA *HOTTIP* is a critical gene in various diseases, including HSCR. No epidemiological studies have explored the correlation between lncRNA *HOTTIP* single nucleotide polymorphisms (SNPs) and HSCR risk. We here lead as a pioneer to explore whether SNPs in lncRNA *HOTTIP* impact the risk of HSCR and HSCR subtypes in an unrelated Chinese population.

Methods: We used the TaqMan method to genotype rs3807598 C>G of the lncRNA *HOTTIP* gene using 1470 HSCR cases and 1473 healthy controls. Of them, 1441 cases and 1434 controls were successfully genotyped. We adopted odds ratios (ORs) and 95% confidence intervals (CIs) to quantify the relationship.

Results: We got an unexpected outcome that lncRNA *HOTTIP* SNP rs3807598 C>G could not modify the risk of HSCR (CG vs. CC: adjusted OR=0.89, 95% CI=0.74–1.07; GG vs. CC: adjusted OR=1.10, 95% CI=0.89–1.37; GG/CG vs. CC: adjusted OR=0.95, 95% CI=0.80–1.13; and GG vs. CC/CG: adjusted OR=1.19, 95% CI=0.99–1.43). What's more, risk effect of lncRNA *HOTTIP* rs3807598 C>G is still not obvious in stratification analysis by HSCR subtype.

Conclusion: Our studies did not provide statistical evidence of a correlation between lncRNA *HOTTIP* SNP rs3807598 C>G and susceptibility of HSCR in the Chinese population that is being studied. Further validation study with a larger sample size covering multi-ethnic groups is warranted.

Keywords: Hirschsprung disease, *HOTTIP*, polymorphism, susceptibility, Chinese

Introduction

Hirschsprung disease (HSCR) is the most frequent disorder of the enteric nervous system (ENS) in children.¹ The prevalence of HSCR is about 1:2000–1:5000 in live births, with a 4:1 male predominance.² Most of the HSCR are originated from defective migration and maturation of intestinal vagal neural cells during embryonal development.³ In over 80% of cases, aganglionosis is confined to the rectosigmoid colon (short-segment HSCR, S-HSCR).⁴ In another 20% of cases, aganglionosis can also affect significant lengths of the colon or even extend proximal to the sigmoid (long segment HSCR, L-HSCR). Extremely rarely (<5% of cases), aganglionosis affects longer tracts of the colon up to a total colonic aganglionosis (TCA) or even total intestinal aganglionosis (TIA).⁵ About 80% of patients present a phenotype as isolated or non-syndromic. The rest of them present a phenotype as syndromic which are accompanied by syndromes, such as Mowat-Wilson syndrome, or chromosomal abnormalities, such as trisomy 21, or other congenital abnormalities.⁶

Correspondence: Wei Zhong
Department of Pediatric Surgery,
Guangzhou Institute of Pediatrics,
Guangdong Provincial Key Laboratory of
Research in Structural Birth Defect
Disease, Guangzhou Women and
Children's Medical Center, Guangzhou
Medical University, 9 Jinsui Road,
Guangzhou 510623, Guangdong, People's
Republic of China
Tel/Fax +86-18902268667
Email zhongwei_gwcmc@163.com

Genetic variations are reported to be closely associated with predisposition to HSCR.^{7–9} Most of the genetic abnormalities in HSCR are found in genes that are known to be a necessity for the proliferation and maintenance of enteric neural crest cell (ENCC) and enteric nervous system (ENS) progenitors.¹⁰ *RET* gene mutations are the most commonly known genetic causes of HSCR, and they take up approximately 50% of familial HSCR and 15–20% of sporadic HSCR.^{11–13} More than 100 mutations in the *RET* gene have been identified in HSCR.¹⁴ Simple genetic mutations of the *RET* gene can cause HSCR by haploinsufficiency. Other major genes implicated in isolated HSCR include *EDNRB*,¹⁵ *EDN3*,¹⁶ *NRG1*,^{17,18} *PHOX2B*,¹⁹ and *SOX10*.²⁰ In addition to the mentioned above, genetic variants in a dozen or more genes were found to predispose to HSCR.^{21,22} Despite the unequivocal implication of these important gene single-nucleotide polymorphisms (SNPs) in HSCR risk, additional SNPs with a modest effect await to be found to fully reveal the etiology of the disease.

Long non-coding RNAs (lncRNAs) are non-protein-coding RNAs that consist of over 200 nucleotides.²³ More than 28,000 lncRNAs are encoded by the mammalian genome, according to the Encyclopedia of DNA Elements Project Consortium (GENCODE release 23). LncRNAs are presumed to have been implicated in various diseases by regulating diverse functions, including epigenetic, transcriptional and posttranscriptional regulation.²⁴ Plenty of lncRNAs have been found to associate with the onset of the HSCR.^{25–27} LncRNA *HOTTIP*, short for *HOXA transcript at the distal tip*, is an enhancer-like lncRNA of the human *HOXA* locus.²⁸ *HOTTIP* possesses great potentiality as a critical regulator in various diseases, including HSCR. SNPs, the most common type of genetic variation, affect the functions of lncRNAs by altering the secondary structure of lncRNAs or the expression of their coding genes.²⁹ Indeed, recent efforts for the lncRNA *HOTTIP* gene identified several SNPs with strong effects on disease risk. However, the relevance of the vital lncRNA *HOTTIP* gene SNPs to HSCR risk has not been reported so far. Considering the important role of lncRNA *HOTTIP* in various diseases, it is reasonable to investigate lncRNA *HOTTIP* gene SNPs to add a bit evidence to fully unveil the genetic spectrum of HSCR. HSCR is a heterogeneous disease, and different patients may be diagnosed with varied clinical manifestations. Each specific type of HSCR may have a specific genetic background. Therefore, it is of necessity to further perform subgroup detections in HSCR.

To shed light on this topic, we explored the correlation between lncRNA *HOTTIP* SNPs and the risk of HSCR using a set of 1470 HSCR cases and 1473 controls. Our findings aid in understanding genetic architectures and the etiology of HSCR.

Materials and Methods

Study Subjects

This research project was approved by the institutional review board of Guangzhou Women and Children's medical center. Written informed consent was obtained from each subject's guardians prior to recruitment. 1470 cases diagnosed with HSCR by pathological analysis after surgery were enrolled. According to the segment lengths of aganglionosis, recruited cases were divided into three subgroups: S-HSCR (1033), L-HSCR (294) and TCA (82). 1473 healthy controls without HSCR and neurological related diseases were recruited from the same region as cases. Relevant subjects' descriptions with details could be found in the previously published studies.^{30,31} This study was conducted in accordance with the Declaration of Helsinki.

Genotyping

The potentially functional SNPs were selected by using the NCBI dbSNP database and SNPinfo (<http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>). The following criteria were applied: (1) the minor allele frequency (MAF) reported in HapMap was > 5% for Chinese Han subjects; (2) putative functional potentials SNPs which might affect transcription activity or binding capacity of the microRNA binding site; (3) SNPs covering the exons, introns, 3'-, and 5'-flanking sequences. Based on the criteria, two SNPs rs3807598 C>G and rs1859168 A>C of *HOTTIP* were selected. rs1859168 A>C was not included in the final genotyping due to its linkage disequilibrium ($R^2=0.647$). Genomic DNA was extracted from participants' blood using a TIANamp Blood DNA Kit (TianGen Biotech Co. Ltd., Beijing, China). SNP genotyping of rs3807598 C>G was conducted with TaqMan assay following the standard procedures.^{32–35} We additionally re-genotyped 10% of the samples. A 100% concordant rate indicates the reliability of the genotyping data.

Statistical Analysis

Hardy–Weinberg equilibrium (HWE) test was performed for rs3807598 C>G in controls using a χ^2 test. First, we tested the differences of clinical characteristics in cases

and controls using a χ^2 test. We used multivariable logistic regression analysis to test for an association between SNP rs3807598 C>G and the risk of HSCR. Such association was quantified by odds ratios (ORs) and 95% confidence intervals (CIs). Two-sided $P < 0.05$ indicates differences were statistically significant. We did the statistical analyses using the SAS release 9.1 (SAS Institute, Cary, NC).

Results

Association of SNP rs3807598 C>G with HSCR Risk

Clinical characteristics of the study subjects are depicted in our previous reports. Among 1470 cases and 1473 healthy controls, 1441 cases and 1434 controls were successfully genotyped for *HOTTIP* rs3807598 C>G. The association results for *HOTTIP* rs3807598 C>G and HSCR risk are provided in Table 1. The genotype frequencies for rs3807598 C>G were 27.06% (CC), 48.79% (CG) and 24.15% (GG) in cases and 25.59% (CC), 53.21% (CG) and 21.20% (GG) in controls. We found no evidence of association signals between rs3807598 C>G and HSCR risk, after adjustments for age and gender (CG vs CC: adjusted OR=0.89, 95% CI=0.74–1.07; GG vs CC: adjusted OR=1.10, 95% CI=0.89–1.37; GG/CG vs CC: adjusted OR=0.95, 95% CI=0.80–1.13; and GG vs CC/CG: adjusted OR=1.19, 95% CI=0.99–1.43).

Stratification Analysis

HSCR is a heterogenous disease characterized by widely clinical features, such as the aganglionosis lengths of the colon. SNPs might have played a specific role in a specific subtype of HSCR. Therefore, we assessed whether the association of rs3807598 C>G might be correlated to a specific HSCR subtype or not, ie S-HSCR, L-HSCR, or TCA (Table 2). In all subtype-stratified analyses, no significant correlations were found between rs3807598 C>G and all specific subtypes.

Discussion

With the list of newly identified lncRNAs with unknown function emerging, there is an urgent need to comprehensively dissect the role of individual lncRNA. In addition, most research paid close attention to the downstream functions of lncRNAs but neglected the relationship between clinical outcome and lncRNAs themselves. SNPs in the lncRNAs represent the original cause for the changing of the downstream functions. In this study, we explored the impact of potential functional SNPs of the *HOTTIP* gene on the HSCR risk using a large-scale sample from the Chinese population.

LncRNA *HOTTIP* gene is located at the homeobox A (*HOXA*) locus (7p15.2). It was originally identified in anatomically distal human fibroblasts and thus termed as “HOXA transcript at the distal tip”. *HOTTIP* could directly bind to WDR5/MLL complexes, and then results in the trimethylation of histone H3 lysine 4 and transcription activation 5' *HOXA* genes.³⁶ The lncRNA *HOTTIP* was found to be implicated in epigenetic alterations and tumorigenesis. Quagliata et al³⁷ detected a significant up regulation of lncRNA *HOTTIP* in hepatocellular carcinoma tissues. High expression of *HOTTIP* is correlated to metastasis formation and serves as a poor prognosis of hepatocellular carcinoma. Xu et al³⁸ determined that *HOTTIP* may exert a tumor suppressor by directly binding and inhibiting the expression of *BRE* in glioma cells. Interestingly, Xie et al³⁹ found that both *HOXA13* and *HOTTIP* were down-regulated in HSCR tissue compared to the control tissues, respectively. Further functional experiments indicated that knockdown of *HOXA13* and *HOTTIP* could inhibit the proliferation and migration of HSCR cells. Wang et al⁴⁰ carried out a case-control study focusing on onco-lncRNAs SNPs and hepatocellular cancer with 521 patients and 817 healthy control in the

Table 1 Association Between *HOTTIP* rs3807598 C>G Polymorphism and Hirschsprung Disease Susceptibility

Genotype	Cases (N=1441)	Controls (N=1434)	P ^a	Crude OR (95% CI)	P	Adjusted OR (95% CI) ^b	P ^b
rs3807598 C>G (HWE=0.012)							
CC	390 (27.06)	367 (25.59)		1.00		1.00	
CG	703 (48.79)	763 (53.21)		0.87 (0.73–1.03)	0.111	0.89 (0.74–1.07)	0.215
GG	348 (24.15)	304 (21.20)		1.08 (0.87–1.33)	0.488	1.10 (0.89–1.37)	0.382
Additive			0.571	1.03 (0.93–1.14)	0.571	1.04 (0.94–1.16)	0.448
Dominant	1051 (72.94)	1067 (74.41)	0.370	0.93 (0.79–1.09)	0.371	0.95 (0.80–1.13)	0.571
Recessive	1093 (75.85)	1130 (78.80)	0.059	1.18 (0.99–1.41)	0.059	1.19 (0.99–1.43)	0.062

Notes: ^a χ^2 test for genotype distributions between Hirschsprung disease patients and controls. ^bAdjusted for age and gender.

Abbreviations: OR, odds ratio; CI, confidence interval; HWE, Hardy–Weinberg equilibrium.

Table 2 Stratification Analysis for the Association Between *HOTTIP* rs3807598 C>G and Hirschsprung Disease Susceptibility (by Subtype)

Variables	rs3807598 (Cases/Controls)		Crude OR	P	Adjusted OR ^a	P ^a
	CC/CG	GG	(95% CI)		(95% CI)	
SHCSR	768/1130	247/304	1.20 (0.99–1.45)	0.067	1.21 (0.99–1.47)	0.064
LHCSR	215/1130	72/304	1.25 (0.93–1.67)	0.146	1.29 (0.95–1.76)	0.104
TCA	60/1130	20/304	1.24 (0.74–2.09)	0.421	1.37 (0.80–2.36)	0.252

Note: ^aAdjusted for age and gender with omitting the corresponding stratification factor.

Abbreviations: OR, odds ratio; CI, confidence interval; SHCSR, short-segment Hirschsprung disease; LHCSR, long-segment Hirschsprung disease; TCA, total colonic aganglionosis.

Chinese population. Among five SNPs in the *HOTTIP* gene (rs3807598, rs17501292, rs2067087, rs17427960, rs78248039) being investigated, rs17501292, rs2067087, and rs17427960 predisposes to an increased risk of hepatocellular cancer. Hu et al⁴¹ revealed that *HOTTIP* rs1859168 C allele was greatly linked to a decreased risk of pancreatic cancer, in both discovery and validation set. Further evidence indicated that decreased *HOTTIP* expression caused by C allele be causative of reduced risk of pancreatic cancer. Richards et al⁴² comprehensively investigated the role of 21 SNPs in *HOXA* lncRNA genes (*HOXA10-AS*, *HOXA11-AS*, and *HOTTIP*) on the risk of epithelial ovarian cancer in 1201 patients and 2009 controls. However, none of the 21 SNPs were correlated with epithelial ovarian cancer risk at a significance threshold, individually. *HOTTIP* SNPs exhibited disease-specific impact patterns. Till now, the role of lncRNA *HOTTIP* SNPs in HSCR risk remains unknown. Considering the vital role of individual *HOTTIP* gene SNPs in cancers and the important role of *HOTTIP* in HSCR, it is of great necessity to further explore the role of *HOTTIP* SNPs in HSCR risk.

Herein, we for the first time explored the correlation of *HOTTIP* SNPs with the HSCR susceptibility using a large sample size population. Unexpectedly, we failed to find a significant correlation between *HOTTIP* SNP rs3807598 C>G with the HSCR susceptibility. HSCR is a complex disease characterized by a combination of genetic and environmental factors. The impact of *HOTTIP* SNP rs3807598 C>G on HSCR risk may be masked by other factors. The joint gene-gene effects may also have a substantial impact on the risk of Hirschsprung disease. An integrative investigation by Gui et al⁴³ found the interaction of variants in *RET* and *NRG1* increases the risk to HSCR development. A single variant may only have a marginal influence on the risk of HSCR. Thus, it is tempting to speculate that this could in part

explain such null impact of *HOTTIP* SNP rs3807598 C>G. Each specific type of HSCR may have a specific genetic background. Therefore, we further perform subgroup detections in HSCR. In all subtype-stratified analyses, no significant correlations were detected between rs3807598 C>G and all specific subtypes. Further study is required to validate the association in an independent cohort.

This study represents the first attempt to determine the relevance of *HOTTIP* gene SNPs to HSCR risk. The relatively large-scale sample size is the major advantage of our study. The study also has some limitations. Firstly, although the largest study conducted to-date with sample size exceeds 1,000, the statistical power in subgroup analysis was still limited. In addition, the studied population was restricted to the Han Chinese. The findings from the Asian based studies may not be applied to other ethnicities. Besides, we only analyzed one SNP here, more should be included in the future. Last, this study only estimated the significantly associated variants in the *HOTTIP* gene. Incorporation of environmental factors, gene-environment interactions, and functional evaluations subject to the association of *HOTTIP* SNPs for HSCR is required.

Conclusion

In summary, we failed to detect a correlation between HSCR risk and SNP rs3807598 C>G in the *HOTTIP* gene in the Chinese population. Beyond doubt, this first description of *HOTTIP* gene SNP and HSCR risk sheds light on the etiology of this intestinal disorder and emphasizes the need to expand our knowledge about lncRNAs SNPs in HSCR. Future investigation focus on this point in a larger sample size should be warranted.

Acknowledgments

This study was funded by grants from the Natural Science Foundation of Guangdong Province, China (No: 2019

A1515010971), and Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease (No: 2019B030301004).

Disclosure

The authors have no conflicts of interest to declare.

References

- Langer JC. Hirschsprung disease. *Curr Opin Pediatr*. 2013;25(3):368–374. doi:10.1097/MOP.0b013e328360c2a0
- Das K, Mohanty S. Hirschsprung disease - current diagnosis and management. *Indian J Pediatr*. 2017;84(8):618–623. doi:10.1007/s12098-017-2371-8
- Ambartsumyan L, Smith C, Kapur RP. Diagnosis of Hirschsprung disease. *Pediatr Dev Pathol*. 2020;23(1):8–22. doi:10.1177/1093526619892351
- Ruiz Aja E, Vega Hernandez L, Martinez Ezquerro N, De Diego Garcia E, Perez Marrodan A, Alvarez-Buhilla PL. Genetic, population and phenotypic characteristics of patients with Hirschsprung disease. *Cir Pediatr*. 2012;25(3):135–139.
- Wang XJ, Camilleri M. Hirschsprung disease: insights on genes, penetrance, and prenatal diagnosis. *Neurogastroenterol Motil*. 2019;31(11):e13732. doi:10.1111/nmo.13732
- Butler Tjaden NE, Trainor PA. The developmental etiology and pathogenesis of Hirschsprung disease. *Transl Res*. 2013;162(1):1–15. doi:10.1016/j.trsl.2013.03.001
- Borrego S, Wright FA, Fernandez RM, et al. A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma. *Am J Hum Genet*. 2003;72(1):88–100. doi:10.1086/345466
- Xie X, He Q, Huang L, et al. Associations of SLC6A20 genetic polymorphisms with Hirschsprung's disease in a Southern Chinese population. *Biosci Rep*. 2019;39(8). doi:10.1042/BSR20182290
- Fadista J, Lund M, Skotte L, et al. Genome-wide association study of Hirschsprung disease detects a novel low-frequency variant at the RET locus. *Eur J Hum Genet*. 2018;26(4):561–569. doi:10.1038/s41431-017-0053-7
- Heanue TA, Pachnis V. Enteric nervous system development and Hirschsprung's disease: advances in genetic and stem cell studies. *Nat Rev Neurosci*. 2007;8(6):466–479. doi:10.1038/nrn2137
- Wang H, Li Q, Zhang Z, Xiao P, Li L, Jiang Q. Functional studies on novel RET mutations and their implications for genetic counseling for Hirschsprung Disease. *Front Genet*. 2019;10:924. doi:10.3389/fgene.2019.00924
- Wang Y, Jiang Q, Cai H, et al. Genetic variants in RET, ARHGEF3 and CTNNAL1, and relevant interaction networks, contribute to the risk of Hirschsprung disease. *Aging (Albany NY)*. 2020;12(5):4379–4393. doi:10.18632/aging.102891
- Wu W, Lu L, Xu W, et al. Whole exome sequencing identifies a novel pathogenic RET variant in Hirschsprung disease. *Front Genet*. 2018;9:752. doi:10.3389/fgene.2018.00752
- Emison ES, McCallion AS, Kashuk CS, et al. A common sex-dependent mutation in a RET enhancer underlies Hirschsprung disease risk. *Nature*. 2005;434(7035):857–863. doi:10.1038/nature03467
- Wu TT, Tsai TW, Chu CT, et al. Low RET mutation frequency and polymorphism analysis of the RET and EDNRB genes in patients with Hirschsprung disease in Taiwan. *J Hum Genet*. 2005;50(4):168–174. doi:10.1007/s10038-005-0236-x
- Sanchez-Mejias A, Fernandez RM, Lopez-Alonso M, Antinolo G, Borrego S. New roles of EDNRB and EDN3 in the pathogenesis of Hirschsprung disease. *Genet Med*. 2010;12(1):39–43. doi:10.1097/GIM.0b013e3181c371b0
- Luzon-Toro B, Torroglosa A, Nunez-Torres R, et al. Comprehensive analysis of NRG1 common and rare variants in Hirschsprung patients. *PLoS One*. 2012;7(5):e36524. doi:10.1371/journal.pone.0036524
- Garcia-Barcelo MM, Tang CS, Ngan ES, et al. Genome-wide association study identifies NRG1 as a susceptibility locus for Hirschsprung's disease. *Proc Natl Acad Sci U S A*. 2009;106(8):2694–2699. doi:10.1073/pnas.0809630105
- Trochet D, O'Brien LM, Gozal D, et al. PHOX2B genotype allows for prediction of tumor risk in congenital central hypoventilation syndrome. *Am J Hum Genet*. 2005;76(3):421–426. doi:10.1086/428366
- Pingault V, Bondurand N, Kuhlbrodt K, et al. SOX10 mutations in patients with Waardenburg-Hirschsprung disease. *Nat Genet*. 1998;18(2):171–173. doi:10.1038/ng0298-171
- Tang CS, Cheng G, So MT, et al. Genome-wide copy number analysis uncovers a new HSCR gene: NRG3. *PLoS Genet*. 2012;8(5):e1002687. doi:10.1371/journal.pgen.1002687
- Kim JH, Cheong HS, Sul JH, et al. A genome-wide association study identifies potential susceptibility loci for Hirschsprung disease. *PLoS One*. 2014;9(10):e110292. doi:10.1371/journal.pone.0110292
- Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. *Nat Rev Genet*. 2009;10(3):155–159. doi:10.1038/nrg2521
- Dykes IM, Emanuelli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. *Genom Proteom Bioinf*. 2017;15(3):177–186. doi:10.1016/j.gpb.2016.12.005
- Li Y, Zhou L, Lu C, et al. Long non-coding RNA FAL1 functions as a ceRNA to antagonize the effect of miR-637 on the down-regulation of AKT1 in Hirschsprung's disease. *Cell Prolif*. 2018;51(5):e12489. doi:10.1111/cpr.12489
- Shen Z, Du C, Zang R, et al. Microarray expression profiling of dysregulated long non-coding RNAs in Hirschsprung's disease reveals their potential role in molecular diagnosis. *Neurogastroenterol Motil*. 2016;28(2):266–273. doi:10.1111/nmo.12722
- Su Y, Wen Z, Shen Q, et al. Long non-coding RNA LOC100507600 functions as a competitive endogenous RNA to regulate BMI1 expression by sponging miR128-1-3p in Hirschsprung's disease. *Cell Cycle*. 2018;17(4):459–467. doi:10.1080/15384101.2017.1403688
- Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. *Cell*. 2007;129(7):1311–1323. doi:10.1016/j.cell.2007.05.022
- Kumar V, Westra HJ, Karjalainen J, et al. Human disease-associated genetic variation impacts large intergenic non-coding RNA expression. *PLoS Genet*. 2013;9(1):e1003201. doi:10.1371/journal.pgen.1003201
- Zhao J, Zhu Y, Xie X, et al. Pleiotropic effect of common PHOX2B variants in Hirschsprung disease and neuroblastoma. *Aging (Albany NY)*. 2019;11(4):1252–1261. doi:10.18632/aging.101834
- Zhang Y, Xie X, Zeng J, et al. Association of NRG1 and AUTS2 genetic polymorphisms with Hirschsprung disease in a South Chinese population. *J Cell Mol Med*. 2018;22(4):2190–2199. doi:10.1111/jcmm.13498
- He J, Wang F, Zhu J, et al. Association of potentially functional variants in the XPG gene with neuroblastoma risk in a Chinese population. *J Cell Mol Med*. 2016;20(8):1481–1490. doi:10.1111/jcmm.12836
- He J, Yang T, Zhang R, et al. Potentially functional polymorphisms in the LIN28B gene contribute to neuroblastoma susceptibility in Chinese children. *J Cell Mol Med*. 2016;20(8):1534–1541. doi:10.1111/jcmm.12846
- He J, Zou Y, Liu X, et al. Association of common genetic variants in pre-microRNAs and neuroblastoma susceptibility: a two-center study in Chinese children. *Mol Ther Nucleic Acids*. 2018;11:1–8. doi:10.1016/j.omtn.2018.01.003

35. He J, Zhang X, Zhang J, et al. LMO1 super-enhancer polymorphism rs2168101 G>T correlates with decreased neuroblastoma risk in Chinese children. *J Cancer*. 2018;9(9):1592–1597. doi:10.7150/jca.24326
36. Wang KC, Yang YW, Liu B, et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. *Nature*. 2011;472(7341):120–124. doi:10.1038/nature09819
37. Quagliata L, Matter MS, Piscuoglio S, et al. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. *Hepatology*. 2014;59(3):911–923. doi:10.1002/hep.26740
38. Xu LM, Chen L, Li F, et al. Over-expression of the long non-coding RNA HOTTIP inhibits glioma cell growth by BRE. *J Exp Clin Cancer Res*. 2016;35(1):162. doi:10.1186/s13046-016-0431-y
39. Xie H, Zhu D, Xu C, et al. Long none coding RNA HOTTIP/HOXA13 act as synergistic role by decreasing cell migration and proliferation in Hirschsprung disease. *Biochem Biophys Res Commun*. 2015;463(4):569–574. doi:10.1016/j.bbrc.2015.05.096
40. Wang BG, Xu Q, Lv Z, et al. Association of twelve polymorphisms in three onco-lncRNA genes with hepatocellular cancer risk and prognosis: a case-control study. *World J Gastroenterol*. 2018;24(23):2482–2490. doi:10.3748/wjg.v24.i23.2482
41. Hu P, Qiao O, Wang J, et al. rs1859168 A > C polymorphism regulates HOTTIP expression and reduces risk of pancreatic cancer in a Chinese population. *World J Surg Oncol*. 2017;15(1):155. doi:10.1186/s12957-017-1218-0
42. Richards EJ, Permeth-Wey J, Li Y, et al. A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer. *Oncotarget*. 2015;6(33):34745–34757. doi:10.18632/oncotarget.5784
43. Gui H, Tang WK, So MT, et al. RET and NRG1 interplay in Hirschsprung disease. *Hum Genet*. 2013;132(5):591–600. doi:10.1007/s00439-013-1272-9

Pharmacogenomics and Personalized Medicine

Dovepress

Publish your work in this journal

Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability. This journal is indexed

on the American Chemical Society's Chemical Abstracts Service (CAS). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/pharmacogenomics-and-personalized-medicine-journal>